A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the rate of stroke, according to a randomized trial presented at the American College of Cardiology’s Annual Scientific Session.